The Pharma Letter2d
Royalty Pharma inks R&D funding deal with Biogen
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding for the US biotech ...
Royalty Pharma announces R&D funding collaboration with Biogen
Royalty Pharma (RPRX) announced that it has entered into an agreement with Biogen (BIIB) to provide research and development funding of up to ...
Hosted on MSN14d
Chou2 Pharma Launches Study on Potential Epilepsy Treatment for Dogs
will lay the groundwork for a subsequent proof-of-concept efficacy study in dogs diagnosed with epilepsy. The experimental therapy is built on Chou2 Pharma’s precision cannabinoid formulating ...
The Business Journals24d
Early-stage biotechs may soon get their swagger back, say industry leaders
In the tough market conditions last year, investors and big pharma companies were more likely ... “So maybe they start to feel comfortable with some proof-of-concept data, but not a whole ...
Exxel Pharma's Innovative Small Molecule, EX937, Rapidly Advancing Toward First-In-Human Study for the Treatment of Refractory Chronic Cough
Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total ...
Yahoo Finance18d
CHOU2 PHARMA Partners with Ethos Discovery to Study Potential New Therapy for Canine Idiopathic Epilepsy
Jan. 27, 2025 /PRNewswire/ -- Chou2 Pharma LLC, a company focused on advancing ... early this year and will be followed by a subsequent proof of concept efficacy study in dogs with epilepsy.
Algiax Pharmaceuticals: Algiax Announces Positive Data from Phase 2a Proof of Concept Study Evaluating AP-325 in Patients with Neuropathic Pain
Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...
Royalty Pharma plc: Royalty Pharma Announces R&D Funding Collaboration With Biogen
Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...